Neurocrine Biosciences | NBIX - Assets


Neurocrine Biosciences reported $5.36B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Prothena USD 349.89M 23.09M Mar/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Repligen USD 2.95B 19.41M Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Teva Pharmaceutical Industries USD 39.86B 183M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026